By Counterforce Health Team in Filsuvez (birch triterpenes topical gel) —

Get Filsuvez Covered by Humana in Georgia: Prior Authorization Requirements and Appeals Process

Answer Box: Quick Path to Approval

To get Filsuvez covered by Humana in Georgia: Submit prior authorization with genetic EB confirmation (COL7A1 for dystrophic, LAMA3/LAMB3/LAMC2 for junctional), documented failure of standard wound care, and wound measurements showing 10-50 cm² partial-thickness wounds present ≥3 weeks. Must be prescribed by dermatologist/wound specialist. If denied, file internal appeal within 65 days, then external review within 4 months through Georgia DOI. Start today: Contact your EB specialist to initiate prior authorization through Humana's provider portal.

Table of Contents

  1. Humana's Coverage Policy Overview
  2. FDA Indication Requirements
  3. Step Therapy & Required Trials
  4. Quantity Limits & Renewal Requirements
  5. Required Diagnostics & Documentation
  6. Specialty Pharmacy Requirements
  7. Evidence for Medical Necessity
  8. Sample Medical Necessity Letter
  9. Common Denial Reasons & Solutions
  10. Appeals Process in Georgia
  11. Cost Assistance Options
  12. FAQ

Humana's Coverage Policy Overview

Humana requires prior authorization for Filsuvez across all plan types in Georgia—Medicare Advantage, commercial, and Medicaid managed care. The medication falls under specialty pharmacy coverage with strict medical necessity criteria that must be met before approval.

Plan Types in Georgia:

  • Medicare Advantage: Follows CMS guidelines with Humana-specific formulary placement
  • Commercial Plans: Subject to employer group variations but consistent PA requirements
  • Medicaid Managed Care: Additional state-specific documentation may apply
Note: Humana's prior authorization denial rate for Medicare Advantage is approximately 3.5%—among the lowest of major insurers—but denials often stem from incomplete documentation rather than medical necessity disputes.

FDA Indication Requirements

Filsuvez received FDA approval in December 2024 for wound care in patients with junctional or dystrophic epidermolysis bullosa who are at least 6 months old. Humana's coverage aligns strictly with this FDA-approved indication.

Covered Diagnoses:

  • Junctional epidermolysis bullosa (JEB)
  • Dystrophic epidermolysis bullosa (DEB)
  • Patient must be ≥6 months of age

Non-Covered Uses:

  • Other wound types or skin conditions
  • Combination with gene therapies like Vyjuvek
  • Wounds with evidence of squamous cell carcinoma

The FDA labeling specifically limits use to partial-thickness wounds in confirmed EB patients, and Humana does not approve off-label applications.

Step Therapy & Required Trials

Before approving Filsuvez, Humana requires documented failure or contraindication to standard wound care therapies. This step therapy requirement is designed to ensure conservative treatments have been attempted.

Required Prior Treatments (must document trial and outcome):

  • Non-adherent dressings (Mepitel, Adaptic, Vaseline gauze)
  • Topical antibiotics or antimicrobials
  • Hydrogel, silicone, or foam dressings
  • Silver sulfadiazine or wound cleansers

Documentation Requirements:

  • Specific products tried and duration of use
  • Clinical response or lack thereof
  • Reasons for discontinuation (ineffective, intolerance, contraindication)
  • Photos or measurements showing wound progression
Tip: Maintain detailed wound care logs throughout conservative treatment to streamline the prior authorization process.

Quantity Limits & Renewal Requirements

Filsuvez is subject to strict quantity controls through Humana's specialty pharmacy program. Each tube is single-use after opening, and quantities are calculated based on wound size and dressing change frequency.

Quantity Controls:

  • Monthly limits based on wound surface area and prescribed frequency
  • Aligned with FDA dosing recommendations
  • Subject to clinical review for quantities exceeding standard protocols

Renewal Requirements:

  • Clinical documentation every 3-6 months
  • Progress notes showing wound improvement or stabilization
  • Updated wound measurements and photographs
  • Continued care by EB specialist required

Prescribers must submit renewal documentation demonstrating ongoing medical necessity and appropriate clinical response.

Required Diagnostics & Documentation

Humana requires comprehensive diagnostic confirmation and clinical documentation to establish medical necessity for Filsuvez coverage.

Coverage at a Glance

Requirement What It Means Where to Find It Source
Genetic Testing COL7A1 (DEB) or LAMA3/LAMB3/LAMC2 (JEB) confirmation Commercial labs, EB centers DEBRA Diagnostic Guide
Wound Criteria 10-50 cm², ≥3 weeks duration, adequate granulation Clinical measurements, photos Filsuvez Prescribing Info
Prior Treatments Documented trial/failure of standard care Medical records, wound logs Provider documentation
Specialist Prescription Dermatologist or wound care expert Provider credentials Humana PA requirements
No Active Infection Clinical assessment, cultures if indicated Lab results, clinical notes FDA labeling requirements

Essential Documentation:

  • Genetic test results confirming EB subtype
  • Wound photographs with measurements
  • Complete treatment history with outcomes
  • Specialist consultation notes
  • Current clinical assessment ruling out infection/malignancy

Specialty Pharmacy Requirements

Filsuvez is a limited distribution drug that must be dispensed through designated specialty pharmacies. Humana contracts with specific pharmacies for specialty medication fulfillment.

Dispensing Requirements:

  • Must use Humana-designated specialty pharmacy (such as Pantherx)
  • Cannot be filled at retail pharmacies
  • Requires coordination between prescriber and specialty pharmacy
  • Temperature-controlled shipping and storage protocols

Patient Responsibilities:

  • Coordinate delivery scheduling
  • Ensure proper storage conditions
  • Report any shipping or product quality issues
  • Maintain communication with specialty pharmacy team

Evidence for Medical Necessity

When submitting prior authorization requests or appeals, include evidence-based support for Filsuvez use in epidermolysis bullosa wound care.

Key Evidence Sources:

  • FDA approval documentation for JEB and DEB
  • Clinical trial data supporting efficacy
  • EB specialist society recommendations
  • Peer-reviewed literature on birch triterpenes

Citing Guidelines: Reference the FDA labeling as primary evidence, supplemented by clinical studies demonstrating wound healing benefits in EB populations. Avoid citing preliminary or non-peer-reviewed sources.

Sample Medical Necessity Letter

Template Structure for Prescribers:

"Patient [Name] has genetically confirmed [dystrophic/junctional] epidermolysis bullosa with mutations in [specific gene]. Current partial-thickness wounds measure [X cm²] and have persisted for [X weeks] despite trials of [list specific prior treatments and durations]. Wounds demonstrate adequate granulation tissue without active infection or malignancy. Conservative wound care has failed to achieve closure, and Filsuvez represents the FDA-approved standard of care for this rare disease indication. Clinical monitoring will continue with wound assessment every [frequency] to evaluate treatment response."

Common Denial Reasons & Solutions

Denial Reason How to Overturn Required Documentation
Missing EB subtype confirmation Submit genetic test results COL7A1 or LAMA3/LAMB3/LAMC2 reports
Insufficient prior therapy documentation Provide detailed treatment history Medical records with dates, products, outcomes
Wound doesn't meet size/duration criteria Submit current measurements and timeline Photos, clinical notes, wound assessment
Not prescribed by specialist Obtain consultation or transfer care Dermatologist or wound care specialist prescription
Quantity exceeds approved limits Justify based on wound burden Clinical rationale for increased frequency
From our advocates: We've seen cases where initial denials were overturned simply by submitting the genetic testing report that was missing from the original PA request. Always ensure all required documentation is included before submitting.

Appeals Process in Georgia

If Humana denies coverage for Filsuvez, Georgia residents have specific appeal rights and timelines that must be followed.

Step-by-Step Appeals Process

  1. Internal Appeal (First Level)
    • Timeline: Must file within 65 calendar days of denial notice
    • How to Submit: Humana Grievance and Appeal Department
      • Mail: PO Box 14638, Lexington, KY 40512-4638
      • Phone: 1-800-233-4013
      • Fax: 1-920-339-2112
    • Decision Timeline: 30 days for standard, 72 hours for expedited
  2. External Review (Independent)
    • Timeline: Must request within 4 months of final internal denial
    • How to Submit: Through Georgia Department of Insurance Consumer Services
    • Cost: Free to consumer
    • Decision Timeline: 45 days standard, 72 hours expedited
  3. Expedited Review Criteria
    • Delay could seriously jeopardize health or ability to regain maximum function
    • Requires physician certification of urgency
    • Available for both internal and external review levels

Georgia-Specific Rights

Under Georgia law, you have the right to external review for medical necessity denials. The Georgia Office of Commissioner of Insurance oversees this process and can be contacted at 1-800-656-2298 for assistance.

Required Documents for Appeal:

  • Original denial letter
  • All supporting medical records
  • Physician letter of medical necessity
  • Genetic testing results
  • Documentation of prior treatment failures

Cost Assistance Options

Given Filsuvez's high cost (approximately $27,631 for common quantities), several assistance programs may help reduce patient financial burden.

Available Programs:

  • Manufacturer Support: Check Filsuvez patient resources for copay assistance programs
  • Foundation Grants: Organizations supporting rare disease patients may provide financial assistance
  • State Programs: Georgia may have additional assistance for rare disease medications
Note: Assistance program eligibility varies by insurance type and income level. Commercial insurance patients typically have more options than Medicare beneficiaries.

FAQ

How long does Humana prior authorization take in Georgia? Standard PA decisions are made within 30 days, but expedited requests can be processed within 72 hours if medical urgency is documented.

What if Filsuvez is not on Humana's formulary? You can request a formulary exception through the same prior authorization process, providing evidence of medical necessity and lack of suitable alternatives.

Can I request an expedited appeal? Yes, if delay in treatment could seriously jeopardize your health. Your physician must provide written certification of medical urgency.

Does step therapy apply if I've tried treatments outside Georgia? Yes, documented treatment history from any location is acceptable as long as medical records clearly show the therapies tried and their outcomes.

Who can prescribe Filsuvez for Humana coverage? Must be prescribed by or in consultation with a dermatologist or wound care specialist with expertise in epidermolysis bullosa.

What happens if my appeal is denied? You can pursue external review through the Georgia Department of Insurance, which provides an independent medical review at no cost to you.

When navigating insurance coverage for rare disease treatments like Filsuvez, having expert guidance can make the difference between approval and denial. Counterforce Health specializes in turning insurance denials into targeted, evidence-backed appeals by analyzing denial letters, plan policies, and clinical notes to draft point-by-point rebuttals aligned to each payer's specific requirements. Their platform helps patients, clinicians, and specialty pharmacies get prescription drugs approved by identifying the exact denial basis and weaving together the right clinical evidence and procedural requirements for successful appeals.

Remember that this information is for educational purposes only and does not constitute medical or legal advice. For personalized assistance with your specific situation, consult with your healthcare provider and consider contacting the Georgia Department of Insurance Consumer Services at 1-800-656-2298.

Sources & Further Reading

Disclaimer: This article is for informational purposes only and does not constitute medical, legal, or insurance advice. Coverage policies and requirements may change. Always verify current information with your insurer and healthcare providers before making treatment decisions.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.